Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

meningitis B

- PMLiVE

GSK and Vir Biotech expand phase 3 COVID-19 antibody study

Study extends into additional sites after positive safety assessment

- PMLiVE

GSK chief exec ‘optimistic’ COVID-19 vaccine could be available next year

GSK is currently partnering with Sanofi on a COVID-19 vaccine project

- PMLiVE

Sanofi, GSK to launch human trials of COVID-19 vaccine

Vaccine combines Sanofi’s baculovirus expression system and GSK’s AS03 adjuvant

- PMLiVE

GSK doses first patients in phase 3 meningitis vaccine trial

Clinical programme will test five-in-one vaccine candidate

- PMLiVE

UK agrees on COVID-19 vaccine deals with J&J and Novavax

Initial agreement secures 90 million doses

- PMLiVE

US secures 100 million doses of Sanofi/GSK’s COVID-19 vaccine

Both companies are also in talks with EU for access to candidate

Secondary effects of COVID-19 on the healthcare system and patients

We are getting to the point where we need to start considering the long-term effects on the healthcare system when making decisions.

Impetus Digital

- PMLiVE

UK government and GSK/Sanofi sign COVID-19 vaccine supply deal

UK adds to its arsenal of potential vaccine candidates

- PMLiVE

GSK agrees on 10% equity stake in mRNA specialist CureVac

Equity investment totals £130m with an upfront payment of £104m

- PMLiVE

GSK signs deal with Medicago for COVID-19 vaccine

Collaboration will utilise GSK’s pandemic adjuvant platform

- PMLiVE

Britain closes in on £500m COVID-19 vaccine deal with Sanofi/GSK

Alleged deal could include agreement for 60 million doses

- PMLiVE

GSK seeks EU approval for Trelegy in adult asthma patients

If approved would open up a large market for the triple therapy

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links